Edgewise Therapeutics Inc (EWTX)
17.55
+0.08
(+0.46%)
USD |
NASDAQ |
Sep 06, 16:00
17.54
-0.01
(-0.06%)
After-Hours: 20:00
Edgewise Therapeutics Cash from Financing (TTM): 295.80M for June 30, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 295.80M |
March 31, 2024 | 294.22M |
December 31, 2023 | 53.17M |
September 30, 2023 | -0.124M |
June 30, 2023 | 129.78M |
March 31, 2023 | 129.59M |
December 31, 2022 | 129.64M |
September 30, 2022 | 130.24M |
Date | Value |
---|---|
June 30, 2022 | 0.582M |
March 31, 2022 | -0.493M |
December 31, 2021 | 186.38M |
September 30, 2021 | 281.09M |
June 30, 2021 | 306.20M |
March 31, 2021 | 307.23M |
December 31, 2020 | 120.28M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.493M
Minimum
Mar 2022
307.23M
Maximum
Mar 2021
157.57M
Average
129.78M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
Catalyst Pharmaceuticals Inc | 131.41M |
Vertex Pharmaceuticals Inc | -1.001B |
Sarepta Therapeutics Inc | 79.41M |
Soligenix Inc | 4.004M |
Regenxbio Inc | 94.51M |